Novo Nordisk to launch Wegovy in South Korea mid-October
Danish pharma giant Novo Nordisk A/S is set to launch its blockbuster glucagon-like peptide-1 (GLP-1) therapy, Wegovy (semaglutide), in South Korea’s growing obesity therapeutics market next week, a company official confirmed to BioWorld. While stating …